Remdesivir: An Epidemic Failure


16-10-20 08:56:00,

Published: October 16, 2020

SPR and other independent experts warned early on that the very expensive “anti-viral” drug remdesivir, produced by Gilead and promoted by the media, is a failure. Dr. Paul Marik, author of the EVMS Covid-19 Critical Care Protocol, called remdesivir a “particularly useless drug” and Gilead’s aggressive marketing campaign “Wall Street centered, not patient-centered”.

The newly published results of the global WHO Solidarity trial now confirm that remdesivir reduces neither hospital stay (time to recovery) nor mortality. But remdesivir is not just a “useless drug”, it may in fact be a dangerous one, as its liver and kidney toxicity in covid patients has been widely documented and is currently being investigated by the European Medicines Agency (EMA).

Investigative journalist Dilyana Gaytandzhieva recently revealed how Gilead paid more than $200 million to US doctors and hospitals to promote its drugs despite several hundred drug-related deaths (this is referring to Gilead’s hepatitis C drug, in particular).

Moreover, several of the fraudulent anti-HCQ studies were published by researchers linked to or paid by remdesivir producer Gilead. The WHO trial itself used toxic overdoses of HCQ, as first revealed by US doctor and biohazard expert Meryl Nass in June (the WHO trial was halted thereafter).

Based on current scientific and clinical evidence, it is best to treat high-risk covid patients as early as possible to avoid disease progression and hospitalization. For more information, see the recent video presentation on ambulatory treatment of covid by Dr. Peter McCullough.

See also

 » Lees verder

COVID-19 – Remdesivir: License to Kill. Hydroxychloroquine: Prohibition to Cure. – Global Research


17-07-20 06:34:00,

Remdesivir’s fight against Hydroxychloroquine (HCQ) is somewhat symbolic of the fight of medical journals, of corrupt institutions against field medicine, of the many general practitioners who are at the bedside.

Remdesivir is an expensive molecule, owned by a pharmaceutical company, Gilead Sciences Inc. In the race for a miracle cure for COVID-19, Gilead is trying to win because it can make a lot of money [1].

1] Hydroxychloroquine is a royalty-free, publicly available and very inexpensive molecule. In other words, although it was originally manufactured by a pharmaceutical company, Sanofi, it will not benefit the industry and therefore will not benefit all the people corrupted by it.

Remdesivir’s fight against Hydroxychloroquine is the symbol of the fight of false medicine, big money medicine, against evidence-based medicine, a medicine that can bring big money to the patient (his health), at little or no cost to society.

Hydroxychloroquine (a treatment defended by Professor Raoult in Marseilles, France, among others) is said to be ineffective in COVID-19, even dangerous [2].

This is simply not true. [2]

There is ample evidence that Hydroxychloroquine, whether or not combined with azythromycin and zinc, is effective in inhibiting viral replication in SARS-CoV-2, with a completely satisfactory safety profile, especially for physicians who are used to and authorized to prescribe it. These molecules, chloroquine and hydroxychloroquine, have been known for decades [3]. This is the truth.

Conversely, it is said that Remdesivir is effective and without any particular danger.

This is not true.

Remdesivir can cause severe kidney failure (requiring dialysis, kidney transplant), liver failure, genetic mutation, heart problems up to cardiac arrest, among others [4]. This is the truth.

On the one hand, the [fake] Lancet study [which was retracted] was trying to demolish hydroxychloroquine [5], on the other hand, the New England Journal of Medicine praises Remdesivir [6-7].

In a previous article, I wrote that what the former editors of these journals say is what we should think: corruption and lies at every level [8].

[8] For all doctors of integrity, true scientists, the public, this could even become a criterion of analysis: when a “big” medical journal praises a drug,  » Lees verder

Remdesivir for Covid-19: $1.6 Trillion for a “Modestly Beneficial” Drug? – Global Research


03-07-20 06:28:00,

The U.S. Department of Health and Human Services has recently “bought” all of Gilead Science’s Remdesivir for $1,600 billion. “500,000 doses at $3,200 per patient – to be available to American hospitals but not for other countries”[6] 

That’s $1.6 trillion tax dollars for a virtually untested drug showing only marginal efficacy in the hospital setting.

How could such a thing happen?


If you believe an urgent call from the Yale School of Public Health that was recently published in the American Journal of Epidemiology— the top epidemiology journal in America — hydroxychloroquine (HCQ) + azithromycin is the quickest and most effective way to halt the Covid-19 pandemic.[1]

According to this Yale statement, hydroxychloroquine – a cheap, natural anti-malarial tree-bark known as quinine for 400 years – is highly effective during Phase 1 of Covid-19, while the virus is loading into the body.

As the first line of defense, it should be immediately, freely, and widely available to symptomatic high-risk patients – through doctors’ offices, outpatient clinics, and hospitals across the land.

Indeed, under the directorship of Dr. Anthony Fauci, a National Institute of Allergy and Infectious Diseases (NIAID) a clinical trial had been launched on May 14 to look into it.[2]

The HCQ + azithromycin protocol is being used successfully by France’s top, award-winning microbiologist, Dr. Didier Raoult.  He is director of the Infectious and Tropical Emergent Diseases Research Unit in Marseille (Institut Hospitalo-Universitaire) (IHU), with 200 staff.  Raoult, now almost a celebrity in France, has recently published his protocol and results, showing an overall 1.1% case fatality rate.[3]

The same protocol has also been highly successful in China, India, Senegal, and Brazil.[4]

So why suddenly is the U.S. government and the media ignoring recommendations from these top specialists,[5] and waiting, instead, until people get very sick and hospitalized to treat them with the relatively untested drug, Remdesivir, which is administered intravenously?

Why has the U.S. Department of Health and Human Services just bought up all the Remdesivir it could order – 500,000 doses at $3,200 per patient – to be available to American hospitals but not for other countries?[6]

To put Remdesivir’s cost in perspective,

 » Lees verder